Gilead Sciences (GILD) said on Oct. 22, 2026 that it will acquire an investigational oral drug for inflammatory bowel disease (IBD), and the same day Texas announced a settlement with the company over how it marketed drugs. The stock traded at $156.04 in the latest quote on Oct. 23, 2026, down 0.73% on the day, and the company reports third-quarter earnings on Oct. 29, 2026. Both items show how a large drugmaker tries to build its next product line while managing legal and financial baggage.
Key facts
- Oct. 22, 2026: Gilead announced it would acquire HCXT-2001, an investigational oral IL-23R inhibitor, to strengthen its inflammation pipeline in IBD, according to its release.
- Oct. 22, 2026: Texas Attorney General Ken Paxton announced a settlement with Gilead over claims that it offered improper incentives to medical providers to prescribe its drugs. The settlement amount was in a law firm's release, so we describe it only as a multimillion-dollar payment. The release is from a law firm that supported the case, not from Gilead.
- Oct. 23, 2026: Shares were at $156.04 in the latest quote. The 52-week range is $114.02 to $160.51. Market cap is $193.48B.
- Second quarter ended June 30, 2026: Revenue was $7.80B, higher than a year earlier and above the analyst estimate of $7.40B. Net income was a loss of $10.50B.
- Oct. 29, 2026 (upcoming): Analysts expect third-quarter earnings of $2.18 per share on revenue of $7.81B.
What happened
The theme: replacing what ages out. Large drugmakers earn most of their profit from a handful of medicines whose patents eventually expire. To keep growing, they buy or license experimental drugs from smaller companies. This is expensive and uncertain, because most experimental drugs never reach the market. Gilead's HIV franchise is the engine: HIV revenue was $5.69B in the second quarter of fiscal 2026, by far its largest line. Liver disease brought in $877.0M and oncology $873.0M.
The example. The IBD deal, as the company described it, adds an oral drug that inhibits the IL-23 receptor, part of an inflammation pathway. IBD includes Crohn's disease and ulcerative colitis. As general context, a pill is often easier for patients than the injections and infusions common in that area. The drug is still investigational, meaning it has not been approved. Gilead also said it will present new data on rare liver diseases at the Liver Meeting 2026, and Reuters reported a planned trial combining a Gilead drug with a BioNTech drug in advanced breast cancer. Together these point to a company adding programs in inflammation, liver disease and cancer.
The legal item. The Texas settlement resolves claims that Gilead offered illegal incentives to medical providers to prescribe its drugs over competitors' medications. Based on the release we reviewed, which comes from a law firm and not from Gilead, we cannot say whether Gilead admitted wrongdoing. Compared with a company this size, the payment is small in dollar terms, but such cases can bring added scrutiny of sales practices.
The big loss. The second-quarter loss stands out. Operating income was -$10.39B and net income was -$10.50B, against profits a year earlier, a net income change of -635.5%. Revenue still rose 10.2% from the year-ago quarter and gross margin held near its usual level at 79.8%. The data we have does not name the cause of the loss, so readers should check the company's 10-Q for the specific item.
Why it matters for investors
Five-quarter trend. Operating margin, which is the share of revenue left after running costs, moved like this: 34.9% (June 2025 quarter), 42.8%, 37.7%, 37.2%, then -133.2% in the June 2026 quarter. Net income went from $1.96B to $3.05B, $2.18B, $2.02B, and then the -$10.50B loss. Operating cash flow was $827.0M, $4.11B, $3.33B, $2.54B and $3.57B across the same five quarters. FMP's free cash flow figure for the latest quarter ($3.69B) is above operating cash flow, which looks like a data anomaly in how capital spending is recorded, so we lean on operating cash flow here. The filing is the place to confirm cash trends.
Where the cash goes. In the second quarter, Gilead paid $1.03B in dividends and spent $355.0M on buybacks. The dividend yield is 2.1%. At June 30, 2026 it held $3.18B in cash and short-term investments against $26.25B in total debt, so net debt was $23.07B. Debt to equity is 2.22. The Altman Z score, a bankruptcy-risk gauge where higher is safer, is 3.74, and the Piotroski score, a 0-to-9 measure of financial health, is 5.
Valuation against peers. Trailing price-to-earnings is negative (-60.02) because of the loss, so it is not useful here. Price to free cash flow is 14.66, and price to sales is 6.35. Peers on trailing figures: AbbVie has a P/E of 80.47 and net margin of 9.8%; AstraZeneca 25.56 and 17.0%; GSK 15.78 and 14.5%; Johnson & Johnson 40.00 and 16.2%. Gilead's trailing net margin is -10.6%, the lowest of the group, largely reflecting the Q2 FY2026 loss. FMP's discounted cash flow model, a rough estimate of what future cash is worth today, gives $138.05 per share, below the current price.
Analysts. Of 58 ratings, 39 are Buy, 18 are Hold and 1 is Sell, for a consensus of Buy. The average price target is $156.67, the median is $164.00, and targets range from $126.00 to $185.00. The share price sits close to the average target. Recent actions were maintained ratings, including Bank of America on Oct. 20, 2026 and JP Morgan and Morgan Stanley on Oct. 7, 2026.
Stock Expert AI MoonshotScore. Gilead scores 66.4, rated Strong. By pillar, relative to its sector: momentum 86, quality 80, growth 76, valuation 43 and safety 18. Strong momentum and quality match the steady revenue and high gross margin. The low safety score fits the heavy debt and the recent loss.
What could go wrong
- Debt: Total debt is $26.25B against $3.18B in cash, and acquisitions can add to it.
- Pipeline risk: An experimental drug can fail in trials, and the IBD market is crowded with established treatments.
- Legal and sales-practice scrutiny: The Texas settlement shows sales practices can draw regulatory claims.
- Insider selling: Of the 30 most recent insider filings, those in the last 90 days show 0 open-market purchases and 11 sales. Older filings in that window may be missing. Insider sales are often routine, but there is no insider buying to offset them.
- Valuation: The price is near the top of its 52-week range and close to the average analyst target.
What to watch next
- Oct. 29, 2026 earnings: Compare revenue with the $7.81B estimate and EPS with the $2.18 estimate.
- Explanation of the loss: Look for the 10-Q or the company's commentary to name what drove the second-quarter loss.
- HIV sales: This is the core business. Watch whether growth continues.
- Cash flow and debt: See whether operating cash flow stays strong and how the deal is funded.
- Analyst forecasts: For the period ending March 2028, analysts expect revenue of $7.98B, and for the period ending June 2028, $8.43B, on thin coverage of six analysts.
Frequently asked questions
Q: What did Gilead announce on Oct. 22, 2026?
Gilead said it would acquire HCXT-2001, an investigational oral IL-23R inhibitor for inflammatory bowel disease. The drug is not approved. Separately, Texas announced a settlement with Gilead over claims about improper incentives to medical providers.Q: Why did Gilead report a big loss if revenue grew?
In the quarter ended June 30, 2026, revenue was $7.80B, higher than a year earlier, but net income was -$10.50B. Gross margin stayed at 79.8% and operating cash flow was $3.57B. The data we used does not name the cause of the loss, so readers should check the company's 10-Q.Q: What do analysts think of Gilead stock?
Of 58 ratings, 39 are Buy, 18 are Hold and 1 is Sell. The average price target is $156.67, with a range of $126.00 to $185.00. The stock was at $156.04 in the latest quote on Oct. 23, 2026. These are analyst views, not our recommendation.This is educational content, not investment advice. Past performance does not guarantee future results.